Molecular targeted therapy is the preferred treatment option for patients with advanced or metastatic ccRCC, primarily targeting pathways, such as vascular endothelial growth factor (VEGF), platelet‐derived growth factor receptor (PDGFR), and mechanistic target of rapamycin (mTOR).19 Here, PDGFRB is linked to nonpapillary renal cell carcinoma.